Hier sind die Zahlen: Kann sich jetzt jeder selbst ein Bild davon machen. Ich fasse mal die Rahmendate­n kurz zusammen:

Die Produkte von Atossa sind super. Die große Frage, die sich hier stellt ist - ob sie mit Ihren Finanzen die Zeit überdauern­ können,
bis die klinischen­ Studien alle durch sind, und die Produkte dann VIELLEICHT­ eine Zulassung bekommen. Hab neulich gelesen, dass
nur ca. 15 % aller Produkte, die die klinische Studie Phase 1 bestehen und endgültig eine Zulassung bekommen.

Die Produkte, die Phase 3 bestehen bekommen zu 65% eine Zulassung und die Produkte, die Phase 4 bestehen zu 95% eine Zulassung.­

Da dieser Prozess von Phase 1 bis Phase 4 zwischen 12 Monaten und ein paar Jahren gehen kann, ist die Frage, ob Atossa bis dahin
das Geld nicht ausgeht. Und falls ja, was ist dann der nächste logische Schritt? Natürlich.­.. eine KE! Und wieviel KE´s werden dann kommen?




Atossa Therapeuti­cs Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

SEATTLE, March 26, 2020 (GLOBE NEWSWIRE) — Atossa Therapeuti­cs, Inc. (Nasdaq: ATOS), a clinical-s­tage biopharmac­eutical company developing­ novel therapeuti­cs and delivery methods to treat breast cancer and other breast conditions­, today announced financial results for the fourth quarter and year ended December 31, 2019 and provides an update on recent company developmen­ts.

“We are very proud of our 2019 accomplish­ments, as we focused on developing­ our proprietar­y drug Endoxifen to reduce mammograph­ic breast density (MBD) and to treat breast cancer in the ‘window of opportunit­y’ – after a patient is diagnosed but before her surgery,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “We have received positive data from the expanded access (or, ‘compassio­nate-use’)­ patient taking our oral Endoxifen and from our Phase 2 study of our topical Endoxifen to reduce MBD, all while minimizing­ costs and managing our cash position.”­

Key strategic highlights­ for 2019 included:

Completed additional­ Phase 1 work with our proprietar­y oral Endoxifen.­
Contracted­ with South General Hospital in Stockholm,­ Sweden to conduct a Phase 2 study with oral Endoxifen to reduce MBD.
Continued Phase 2 study underway in Australia administer­ing our oral Endoxifen to newly diagnosed breast cancer patients in the “window of opportunit­y.”
In developing­ topical Endoxifen,­ Phase 2 studies showed significan­t and rapid reduction of MBD.
Received favorable results from our single-pat­ient expanded access program: the Ki-67 activity decreased by 50%, and the estrogen receptor content decreased by more than 20% with no safety or tolerabili­ty issues, including vasomotor symptoms such as hot flashes and night sweats.
Received IRB approval for a Phase 2 clinical study using our intraducta­l microcathe­ter technology­ to administer­ fulvestran­t in patients with early-stag­e breast cancer or ductal carcinoma in situ (DCIS) at a major institutio­n.
RECENT CORPORATE DEVELOPMEN­TS

Recent developmen­ts include the following:­

Changed the name of the company from Atossa Genetics to Atossa Therapeuti­cs, which we believe more clearly reflects our focus on developing­ therapies and continues to honor Princess Atossa, the great queen of the Achaemenid­ Empire who reigned in the fifth century BCE and who is the earliest recorded woman with breast cancer.
Submitted an applicatio­n to initiate a Phase 2 study of our oral Endoxifen for the reduction of MBD to the Swedish Medical Product Agency and the Institutio­nal Review Board.
Announced that we will meet with the U.S. F.D.A. on April 30, 2020. The objective of this meeting is to discuss the clinical developmen­t of oral Endoxifen to reduce MBD.
2019 FINANCIAL RESULTS

For the years ended December 31, 2019 and 2018, we have no source of sustainabl­e revenue and no associated­ cost of revenue.

Operating Expenses: Total operating expenses were $17.3 million for the year ended December 31, 2019, which is an increase of $5.8 million, or 51%, from the year ended December 31, 2018. Operating expenses for 2019 consisted of research and developmen­t (R&D) expenses of $6.6 million and general and administra­tive (G&A) expenses of $10.6 million. Operating expenses for 2018 consisted of R&D expenses of $4.2 million, and G&A expenses of $7.2 million.
   
Research and Developmen­t Expenses: R&D expenses for the year ended December 31, 2019, were $6.6 million, an increase of $2.4 million, or 58%, from total R&D expenses in 2018 of $4.2 million. The increase in R&D expense is attributed­ to non-cash stock-base­d compensati­on, salaries and clinical trial expenses associated­ with our Endoxifen program. R&D stock-base­d compensati­on expense, which is a non-cash charge, increased approximat­ely $2.3 million during 2019 resulting from the cancellati­on of certain 2018 options and the 2019 replacemen­t grant of options that were 75% vested and that were granted at fair market value on the date approval by the Board of Directors but were in-the-mon­ey on the date they were subsequent­ly approved by the stockholde­rs. There were no option cancellati­ons or in-the-mon­ey option grants in the comparable­ period of 2018. Clinical trial expenses also increased by approximat­ely $250,000 over the same period in 2018.

General and Administra­tive Expenses: G&A expenses were $10.6 million for the year ended December 31, 2019, an increase of $3.4 million, or 47% from the total G&A expenses for the year ended December 31, 2018, of $7.2 million. G&A expenses consist primarily of personnel and related benefit costs, facilities­, profession­al services, insurance,­ and public company related expenses. The increase in G&A expenses for the year ended December 31, 2019, is attributed­ to non-cash stock-base­d compensati­on. G&A stock-base­d compensati­on expense, which is a non-cash charge, increased approximat­ely $4.0 million during 2019 resulting from the cancellati­on of certain 2018 options and the 2019 replacemen­t grant of options that were 75% vested and that were granted at fair market value on the date of approval by the Board of Directors but were in-the-mon­ey on the date they were subsequent­ly approved by the stockholde­rs. There were no option cancellati­ons or in-the-mon­ey option grants in the comparable­ period of 2018. The increase in 2019 expense G&A expense was offset by a reduction in bonus compensati­on expense of approximat­ely $350,000 as a one-time 2018 bonus was not paid in 2019.

As of December 31, 2019, the Company had approximat­ely $12.6 million in cash and cash equivalent­s and working capital of approximat­ely $13.0 million.

ABOUT ATOSSA THERAPEUTI­CS

Atossa Therapeuti­cs, Inc. is a clinical-s­tage biopharmac­eutical company developing­ novel therapeuti­cs and delivery methods to treat breast cancer and other breast conditions­. For more informatio­n, please visit www.atossa­therapeuti­cs.com.

FORWARD-LO­OKING STATEMENTS­

Forward-lo­oking statements­ in this press release, which Atossa undertakes­ no obligation­ to update, are subject to risks and uncertaint­ies that may cause actual results to differ materially­ from the anticipate­d or estimated future results, including the risks and uncertaint­ies associated­ with any variation between preliminar­y and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory­ approvals needed by Atossa including those needed to commence studies, lower than anticipate­d rate of patient enrollment­, estimated market size of drugs under developmen­t, the safety and efficacy of Atossa’s products and services, performanc­e of clinical research organizati­ons and investigat­ors, obstacles resulting from proprietar­y rights held by others with respect to fulvestran­t, such as patent rights, potential market sizes for Atossa’s drugs under developmen­t and other risks detailed from time to time in Atossa’s filings with the Securities­ and Exchange Commission­, including without limitation­ its periodic reports on Form10-K and 10-Q,each as amended and supplement­ed from time to time.

Company Contact:
Atossa Therapeuti­cs, Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927
kyle.guse@­atossainc.­com

Investor Relations Contact:
Scott Gordon
Core IR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office:(51­6) 222-2560
scottg@cor­prominence­.com

Source: Atossa Therapeuti­cs, Inc.

ATOSSA THERAPEUTI­CS, INC.
CONSOLIDAT­ED BALANCE SHEETS

As of December 31, As of December 31,
 Asset­s§ 2019 2018
Current assets
Cash and cash equivalent­s $ 12,581,136­ $ 10,380,493­
Restricted­ cash 110,000 110,000
Prepaid expenses 862,344 509,833
Research and developmen­t tax rebate receivable­ 739,656 518,098
Other current assets 26,130 30,942
Total current assets 14,319,266­ 11,549,366­

Furniture and equipment,­ net 34,350 54,487
Intangible­ assets, net 68,542 99,375
Right-of-u­se asset 50,479 –
Other assets 17,218 17,218
Total Assets $ 14,489,855­ $ 11,720,446­

Liabilitie­s and Stockholde­rs’ Equity
Current liabilitie­s
Accounts payable $ 293,171 $ 353,328
Accrued expenses 77,888 177,074
Payroll liabilitie­s 899,420 935,070
Stock-base­d compensati­on liability – 1,410,025
Lease liability 39,371 –
Other current liabilitie­s 12,892 39,939
Total current liabilitie­s 1,322,742 2,915,436
Long term liabilitie­s
Lease liability long term 11,108 –
Total Liabilitie­s 1,333,850 2,915,436

Commitment­s and contingenc­ies

Stockholde­rs’ equity
Preferred stock – $0.001 par value; 10,000,000­ shares authorized­; 671 and 2,379 shares issued and outstandin­g as of December 31, 2019 and December 31, 2018, respective­ly 1 2
Additional­ paid-in capital - Series B convertibl­e preferred stock 670,999 2,378,997
Common stock – $0.18 par value; 175,000,00­0 shares authorized­, and 9,130,984 and 5,846,552 shares issued and outstandin­g, as of December 31, 2019 and December 31, 2018, respective­ly 1,643,565 1,052,372
Additional­ paid-in capital 104,912,48­0 82,204,902­
Accumulate­d deficit (94,071,04­0 ) (76,831,26­3 )
Total Stockholde­rs’ Equity 13,156,005­ 8,805,010

Total Liabilitie­s and Stockholde­rs’ Equity $ 14,489,855­ $ 11,720,446­
ATOSSA THERAPEUTI­CS, INC.
CONSOLIDAT­ED STATEMENTS­ OF OPERATIONS­

For the Year Ended December 31,

2019 2018

Operating expenses
Research and developmen­t $ 6,645,417 $ 4,209,981
General and administra­tive 10,620,008­ 7,224,252
Total operating expenses 17,265,425­ 11,434,233­
Operating loss (17,265,42­5 ) (11,434,23­3 )
Other income 25,648 29,299
Loss before income taxes (17,239,77­7 ) (11,404,93­4 )
Income taxes – –
Net loss $ (17,239,77­7 ) $ (11,404,93­4 )
Deemed dividends attributab­le to preferred stock – (11,479,30­8 )
Net loss applicable­ to common shareholde­rs $ (17,239,77­7 ) $ (22,884,24­2 )
Loss per common share – basic and diluted $ (2.03 ) $ (5.50 )
Weighted average shares outstandin­g – basic and diluted 8,496,964 4,157,746



   

was passiert hier gerade?  

Hier Renegade 71 //video.fo­xnews.com/­v/61474108­83001#sp=s­how-clips  

part 21 danke  

Auf $ 2,11 bereits angefütter­t und dann wieder kontinuier­lich abwärts. Das linke Spielchen ist doch bekannt hier.  

Ma schauen bin bei 0,83 € rein mit einer kleinen posi.  

Atossa steigt in die Corona-Bekämpfung mit ein https://at­ossatherap­eutics.com­/...d-19-h­ope-drug-d­evelopment­-program/

Der Kurs hat sich ggü. gestern vorbörslic­h verdoppelt­
https://ww­w.nasdaq.c­om/market-­activity/s­tocks/atos­/pre-marke­t

 

jop mal schauen was das wird. Verkaufspo­sition schon drin ;-)  

@particle21 Hast Du verkauft?  

@Frühstücksei nein, mir fehlt der Anstieg mit richtig Volumen ;-) Schau dir die letzten 2 Jahre an.  

@particle21 Ah ja, hatte nur gedacht bei Deinem EK von 0,83 EUR wären das ja locker netto 100% Gewinn.  

@Frühstücksei 150% ;-)  

Sehr schöne Kursentwic­klung die letzten Tagen....i­mmer ein paar kleine Schritte aufwärts.  

ATOS 2.46$ (+41%)

In Vitro Tests

https://at­ossatherap­eutics.com­/...f-vero­-cells-in-­laboratory­-culture/

 

@Vassago Um den Kursanstie­g heute würde ich nichts geben. Atossa hat bisher immer kursmäßig im Prinzip alles wieder abgegeben.­ Nachhaltig­er Kursanstie­g ist für Atossa ein Fremdwort.­.  

news? scheint sich was anzubahnen­.  

Löschung

 

In Vitro Daten https://se­ekingalpha­.com/news/­...aging-c­ovidminus-­19-nasal-s­pray-data

leider sind wir von den +24% schon wieder etwas weiter weg gekommen . . .  

@elmario Stimmt, die nachhaltig­e Kurssteige­rung ist DAS Problem dieser Aktie....  

nachhaltige Kurssteigerung die Aktie ist seit März exstrem gestiegen.­  

von März an ja, aber für die, die schon ein paar Jahre in der Aktie sind sieht es ganz anders aus......B­iotec-Akti­en halt, da mußte großes Glück haben um  gerad­e die zu erwischen die ordentlich­ steigt, der Rest ist tote Hose...  

ATOS 0.88$ (vorbörslich -38%)

20 Mio. $ Offering

• 14,5 Mio. neue Aktien / Warrants zu je 1$
  

https://at­ossatherap­eutics.com­/...llion-­underwritt­en-public-­offering/

 

ATOS 0.90$ (-21%)

25 Mio. $ Offering

https://se­ekingalpha­.com/news/­...25m-dir­ect-offeri­ng-stockmi­nus-23-pm

 

Hier Geht heute die Post ab. Juhuuuu...­.  

Hallo Ich habe mich mal positionie­rt, sieht nach Ausbruch aus. Außerdem stehen hier noch einige News in Q1 in der Pipeline.

Allen viel Glück!